GRASSLEY REMINDS PHARMA CEOS HOW MUCH DRUG LIST PRICES MATTER DURING HEARING

The Daily Caller | 2/26/2019 | Staff
megzmegz123 (Posted by) Level 3
Click For Photo: https://cdn01.dailycaller.com/wp-content/uploads/2019/02/chuck-grassley-senate-finance-e1551217453734.jpg

Republican Iowa Sen. Chuck Grassley reminded seven pharmaceutical company executives that drug list prices matter to patients during a Senate Finance Committee hearing on drug prices Thursday.

“For a patient taking a drug that has no competition, the list price becomes very important,” committee chairman Grassley said, according to NPR. “I’ve heard about people skipping doses of their prescription drugs to make them last until the next paycheck.”

Grassley - Committee - Member - Oregon - Sen

Grassley and the committee’s ranking member, Democratic Oregon Sen. Ron Wyden, questioned executives from companies including Johnson & Johnson, AstraZeneca and Pfizer at Thursday’s hearing.

“Last year, Janssen invested $8.4 billion globally in research and development, making Janssen one of the top research and development investors in any industry anywhere in the world,” said Jennifer Taubert, worldwide chairwoman of pharmaceuticals for Johnson & Johnson, which owns Janssen, according to NPR.

Wyden - Grassley - Executives - List - Prices

Wyden and Grassley continued to press the executives for high list prices, even as the CEOs responded by saying list price does not always equate to what patients pay.

“Prescription drugs did not become outrageously expensive by accident,” Wyden...
(Excerpt) Read more at: The Daily Caller
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!